Anoop M Nambiar, M.D.
Dr. Anoop M. Nambiar is an Associate Professor and Founding Director of Center for Interstitial Lung Disease at the University of Texas Health Science Center at San Antonio and specializes in interstitial lung diseases. He completed his undergraduate studies at Rutgers University in New Jersey in 1999. He received his Doctor of Medicine in 2003 at New Jersey Medical School-University of Medicine and Dentistry of New Jersey. In 2006, he completed her internship and residency in internal medicine followed by fellowship in pulmonary and critical care medicine at the University of Michigan. He is an active member of the American Thoracic Society, American College of Chest Physicians, and European Respiratory Society. His program is currently one of 68 Pulmonary Fibrosis Foundation Care Centers in the U.S., one of 5 in Texas, and the only one in South Texas.
- 2016 - Postdoctoral Training - Clinical Investigation - University of Texas Health Science Center at San Antonio
- 2009 - Postdoctoral Fellowship - Pulmonary & Critical Care Medicine - University of Michigan Health System
- 2006 - Residency - Internal Medicine - University of Michigan Health System
- 2004 - Internship - Internal Medicine - University of Michigan Health System
- 2003 - MD - Medicine - University of Medicine & Dentistry of New Jersey-New Jersey Medical School
- 1999 - BA - Molecular Biology & Biochemistry (magna cum laude) - Rutgers, The State University of New Jersey
- 9/2016 - Associate Professor of Medicine and Director of Interstitial Lung Disease Program - University of Texas Health Science Center at San Antonio, Medicine, San Antonio
- 12/2010 - Staff Physician - South Texas Veterans Healthcare System, Medicine, San Antonio
- 11/2010 - Staff Physician - University Hospital, University Health System, Medicine, San Antonio
Instruction & Training
- 12/2014 - Present, ILD/IPF Multidisciplinary Conference, UTHSCSA / VA / UHS
- 12/2010 - Present, Rotation Student Supervision, University Health System/Audie Murphy Memorial Veterans Hospital
- 11/2010 - Present, Rotation Student Supervision, University Health System and Audie Murphy Memorial Veterans Hospital
- 11/2010 - Present, Rotation Student Supervision, University Health System
- 11/2010 - Present, Rotation Student Supervision, University Health Systems (Downtown Clinic)
- 11/2010 - Present, Post Graduate Rotation Supervision, UTHSCSA / VA / UHS
- 8/2010 - Present, Adv Physical Diagnosis, The University of Texas Health Science Center
Research & Grants
Funding Agency NHLBI, NIH Title Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis (CleanUP IPF) Trial within the Pulmonary Trials Cooperative (PTC) Status Active Period 1/2018 - Present Role Contributor Grant Detail Funding Agency Claude D. Pepper OAIC Title Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis Status Active Period 7/2017 - Present Role Principal Investigator Grant Detail Funding Agency Title The MENDS II Study: Maximizing the Efficacy of sedation and reducing neurological dysfunction and mortality in septic patients with acute respiratory failure. Status Complete Period 7/2012 - 6/2017 Role Co-Investigator Grant Detail This mutlicenter, randomized, controlled trial will be evaluating the efficacy and safety of sedation as well as reducing neurological dysfunction and mortality in septic patients with acute respiratory failure. Funding Agency VA Cooperative Trial # 10-04 CSP 574 Title ESCAPe Trial ? Extended Steroid (in) CAP(e): A randomized, Placebo Controlled, Double-Blind Trial to Evaluate the Safety and Efficacy of Methylprednisolone in Hospitalized Veterans with Severe Community-Acquired Pneumonia. Status Complete Period 6/2011 - 6/2016 Role Co-Investigator Grant Detail This very important VA Cooperative Trial is a large, multicenter, randomized, placebo-controlled, double-blinded study to evaluate the safety and efficacy of methylprednisolone in severe community acquired pneumonia (CAP). Recently published observational studies, small randomized controlled studies, and meta-analyses suggest a benefit for the use of corticosteroids in severe CAP. If this study does demonstrate clinical and statistical significance in the improvement of severe CAP outcomes, this would be a landmark, practice-changing trial.
Funding Agency Pulmonary Fibrosis Foundation Title Pulmonary Fibrosis Foundation Registry Status Active Period 7/2016 - Present Role Co-Investigator Grant Detail Funding Agency Boehringer-Ingelheim Title A double blind, randomized, placebo-controlled trial evaluatingthe efficacy and safety of nintedanib over 52 weeks in patientswith Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Status Active Period 11/2017 - Present Role Contributor Grant Detail Funding Agency Pulmonary Fibrosis Foundation Title Pulmonary Fibrosis Foundation Care Center Status Active Period 1/2016 - 7/2018 Role Principal Investigator Grant Detail Funding Agency Roche/Genentech Title A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis (RIFF study) Status Complete Period 8/2013 - 8/2017 Role Principal Investigator Grant Detail The RIFF study is a multinational, multicenter, phase 2, randomized, controlled study to evaluate the efficacy and safety of lebrikizumab, an anti-IL-13 agent, in patients with idiopathic pulmonary fibrosis (IPF). It has been suggested that IL-13 plays a pivotal role in the pathogenesis of IPF. This study aims to determine the efficacy of lebrikizumab, specifically to slow down disease progression as measured by the forced vital capacity at 52 weeks. Other important secondary objectives will assess progression-free survival, mortality, exacerbations, quality of life, and adverse events.
Nambiar AM, Justice J, Pascual RM, Tchkonia T, LeBrasseur N, Kirkland JL, Musi N, Kritchevsky S. Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: an Open-Label Pilot Study of Dasatinib and Quercetin; 2018 Oct. (CHEST International Conference). Castaneda-Nerio JC, Nambiar AM, Restrepo CS. Dendiform Pulmonary Ossification in Interstitial Lung Disease; 2017 May. (American Thoracic Society International Conference 2017). Dreyfuss Z, Nambiar AM. Clogging the Pipes; 2016 Oct. (CHEST International Conference 2016). L.B. Tolle, N. Tayob, A. Nambiar, S.L. Schmidt, A. Flint, A. Lagstein, J.L. Myers, L.A. Schmidt, B. Gross, E. Kazarooni, B. Sundaram, A. Chugtai, G.B. Toews, F.J. Martinez, K.R. Flaherty. The Role Of High-Resolution CT Patterns In Prognosticating IPF Presented at ATS 2014 International Conference in San Diego, CA; 2014 May. (ATS International Conference - 2014).
Amalakuhan B, Nambiar AM. Diagnosis and Management of Thrombotic Thrombocytopenic Purpura. In: Robert C. Hyzy (Editor). Evidence-Based Critical Care: A Case Study Approach. 2018.
Velez MI, Nambiar AM. Combination pirfenidone and inhaled N-acetylcysteine therapy for IPF: Does it take these two to tango? Respirology 2015 Feb;. Nambiar AM. Procalcitonin in Acute Exacerbations of Interstitial Pneumonia: Another Tool in the Toolbox? Respirology 2013 Apr;18(3):389-390.
Joana Alves, Emine Alp, Despoina Koulenti, Zhongheng Zhang, Stephan Ehrmann, Stijn Blot, Matteo Bassetti, Andrew Conway-Morris, Rosa Reina, Enrique Teran, Candela Sole-Lleonart, Maria Ruiz-Rodriguez, Jordi Rello, and the SANEME 2 Study Investigators (Anoop Nambiar, collaborator). Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey European Journal of Clinical Microbiology 2018 Apr;. Salisbury ML, Tolle LB, Xia M, Murray S, Tayob N, Nambiar AM, Schmidt SL, Lagstein A, Myers JL, Gross BH, Kazerooni EA, Sundaram B, Chughtai AR, Martinez FJ, Flaherty KR. Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients Respiratory Medicine 2017 Oct;. Walsh SLF1, Maher TM2, Kolb M3, Poletti V4,5, Nusser R6, Richeldi L7, Vancheri C8, Wilsher ML9, Antoniou KM10, Behr J11, Bendstrup E5, Brown K12, Calandriello L13, Corte TJ14, Cottin V15, Crestani B16, Flaherty K17, Glaspole I18, Grutters J19, Inoue Y20, Kokosi M21, Kondoh Y22, Kouranos V21, Kreuter M23, Johannson K24, Judge E25, Ley B26, Margaritopoulos G21, Martinez FJ27, Molina-Molina M28, Morais A29, Nunes H30, Raghu G31, Ryerson CJ32, Selman M33, Spagnolo P34, Taniguchi H22, Tomassetti S4, Valeyre D30, Wijsenbeek M35, Wuyts W36, Hansell D37, Wells A38; IPF Project Consortium...Nambiar A (collaborator). Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study European Respiratory Journal 2017 Aug;50(2). Nambiar AM, Anzueto AR, Peters JI. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis PloS ONE 2017 Apr;12(4). Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis Am Fam Physician 2016 May;93(10):840-848. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A Phase 3 Trial Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis N Engl J Med 2014 May;370(22):2083-2092. Maselli DJ, Fernandez J, Whong CY, Echevarria K, Nambiar AM, Anzueto AR, Restrepo MI. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia Infect Drug Resist 2012 Feb;5:43-51.
- American Board of Internal Medicine/Pulmonary Disease
- American Board of Internal Medicine/Critical Care Medicine